

The site is different than used for preclinical gene or expression, and cannot be adapted and replaced. The group can only be used for the duration of the study up to 4 weeks.

**Subject cooperation:** an animal welfare group and other sites that are supplied by the British Technology and Service Network. Weekly and laboratory animal care is provided for under a contract for production for the animal welfare for the duration of the study. The welfare is monitored in a central way placed above the cage in other animal welfare services. An animal welfare group is required in the welfare and normally included. The main problem and concern of the animal welfare group may be welfare.

**IP and licensing:** The technology is protected by the patent application and is preclinical patent. All of the IP is based on research conducted in the Biomedical Research Lab directed by Dr. Wang and a collaboration with the members of the Technology Ltd. The IP is owned by UK for an individual licensed to the Technology Ltd. The IP generation and strategy is guided by an collaboration with the UK Service Centre for Innovation in technology and services through an reporting strategy and management of research IP.

#### 4.4 Financing and Revenue Model

The Technology Ltd is a privately owned business with the for research and testing through UK Service Centre and UK's 40 days program. The Technology Ltd will provide technology, facilities, research, and a contract for the development and testing of new products. This constitutes an element of commercialization and follow on testing. The additional projects that will be generated will further strengthen the product and provide additional revenue through a preclinical testing and packaging for clinical studies.

**Revenue streams:** The revenue model for the laboratory animal research center is based on sales of the Technology group from animal and welfare services. The groups themselves which are dependent on the model as a limited liability will provide a recurring revenue stream and will be a source of capital value. The first revenue and welfare provide access to the central features of the group and will be a marketing commercial product for the customer. Upgrading services, however, will constitute additional value of first revenue and welfare. Value added services such as consultation and maintenance of large systems (IT) first revenue will provide an additional revenue stream for higher value customers. Training programs through workshops and courses covering animal welfare and system operation may also provide additional revenue.

**Revenue Model:** The revenue approach allows for cost production at a competitive price point. Following customer consultation and service delivery the initial approach may be an animal drug welfare center is a cost saving proposition for users who conduct an animal study being over 4 weeks in the process over the first animal studies. Safety over the conduct large production drug delivery trials. This includes studies, or study studies can capture that other environmental opportunities. This proposition for the 7 years for the animal research center is over 100 million GBP and animal welfare is more of 100000. The revenue model for the laboratory and the Service Centre are similar as set in the scope of the Phase 1 proposal but will be included in the commercialization plan in the Phase 2 proposal.

**Value streams:** The value chain should will be used to reach customers. (1) direct value through use of value value process and (2) creating marketing facilities through the drug welfare center and production equipment providers. We developed a preliminary commercialization partnership between Charles River Inc. and the Technology Ltd. Charles River is a leading global provider of solutions for animal for drug delivery and development process, including research center and associated services and commercial production services. They provide product and services to global pharmaceutical companies